0001209191-15-061523.txt : 20150717 0001209191-15-061523.hdr.sgml : 20150717 20150717163632 ACCESSION NUMBER: 0001209191-15-061523 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150715 FILED AS OF DATE: 20150717 DATE AS OF CHANGE: 20150717 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Pharma plc CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272179987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 BUSINESS PHONE: 011-353-1-772-2100 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE, 1ST FLOOR STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN STATE: L2 ZIP: 4 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHERMAN JEFFREY W CENTRAL INDEX KEY: 0001230482 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 15994120 MAIL ADDRESS: STREET 1: C/O IDM PHARMA, INC. STREET 2: 9 PARKER, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-07-15 0 0001492426 Horizon Pharma plc HZNP 0001230482 SHERMAN JEFFREY W C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4 IRELAND 0 1 0 0 EVP and Chief Medical Officer Ordinary Shares 2015-07-15 4 M 0 24437 2.40 A 137319 D Ordinary Shares 2015-07-15 4 S 0 24437 35.55 D 112882 D Ordinary Shares 2015-07-15 4 M 0 2450 4.96 A 115332 D Ordinary Shares 2015-07-15 4 S 0 2450 35.55 D 112882 D Stock Option (Right to Buy) 2.40 2015-07-15 4 M 0 24437 0.00 D 2023-01-01 Ordinary Shares 24437 26563 D Stock Option (Right to Buy) 4.96 2015-07-15 4 M 0 2450 0.00 D 2021-12-07 Ordinary Shares 2450 51171 D Includes 10,549 ordinary shares of the Issuer acquired by the reporting person on June 1, 2015 pursuant to an employee stock purchase program. The sales reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the reporting person on May 13, 2015. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.09 to $35.92 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests in 48 equal monthly installments following the date of grant. /s/ Paul W. Hoelscher, Attorney-in-Fact 2015-07-17